$42.16
7.20% yesterday
Nasdaq, Oct 06, 10:16 pm CET
ISIN
US4158581094
Symbol
HROW

Harrow Health, Inc. Stock price

$42.16
+2.39 6.01% 1M
+19.07 82.59% 6M
+8.61 25.66% YTD
-8.48 16.75% 1Y
+30.25 253.99% 3Y
+36.76 680.74% 5Y
+35.16 502.29% 10Y
+33.51 387.48% 20Y
Nasdaq, Closing price Mon, Oct 06 2025
-3.27 7.20%
ISIN
US4158581094
Symbol
HROW
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$1.9b
Net debt
$169.1m
Cash
$53.0m
Shares outstanding
36.7m
Valuation (TTM | estimate)
P/E
negative | 116.8
P/S
7.4 | 5.9
EV/Sales
8.1 | 6.4
EV/FCF
negative
P/B
33.9
Financial Health
Equity Ratio
17.9%
Return on Equity
-25.1%
ROCE
15.0%
ROIC
-
Debt/Equity
4.5
Financials (TTM | estimate)
Revenue
$227.7m | $287.0m
EBITDA
$32.4m | $73.6m
EBIT
$14.4m | $42.1m
Net Income
$-10.2m | $14.3m
Free Cash Flow
$-34.5m
Growth (TTM | estimate)
Revenue
47.7% | 43.8%
EBITDA
689.5% | 211.8%
EBIT
276.6% | 363.9%
Net Income
69.5% | 181.7%
Free Cash Flow
-67.0%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
14.2% | 25.7%
EBIT
6.3%
Net
-4.5% | 5.0%
Free Cash Flow
-15.1%
More
EPS
$-0.3
FCF per Share
$-0.9
Short interest
17.8%
Employees
382
Rev per Employee
$520.0k
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
228 228
48% 48%
100%
- Direct Costs 58 58
30% 30%
25%
170 170
55% 55%
75%
- Selling and Administrative Expenses 142 142
32% 32%
62%
- Research and Development Expense 13 13
30% 30%
6%
32 32
690% 690%
14%
- Depreciation and Amortization 18 18
47% 47%
8%
EBIT (Operating Income) EBIT 14 14
277% 277%
6%
Net Profit -10 -10
70% 70%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
GlobeNewsWire
about 14 hours ago
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx.
Neutral
Seeking Alpha
10 days ago
Harrow, Inc. (NASDAQ:HROW ) Analyst/Investor Day September 26, 2025 11:30 AM EDT Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Conference Call Participants Mayank Mamtani - B. Riley Securities, Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co.,...
Neutral
GlobeNewsWire
11 days ago
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and...
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today